Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0650

0.0%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: NTTG who wrote (12170)	7/3/2013 11:48:56 AM
From: mplaut	2 Recommendations Recommended By Howard Williams Jack Russell Read Replies (1) of 13111

There is no question that PVCT is trying to beat a new path to its goals. Most of your complaints are in comparison to others. Since they are clearly trying a different path, these comparisons are somewhat unfair, even if accurate. There is no other company in the world that has a product that has successfully passed a PII trial and is a candidate for some sort of PIII procedure, that has only 4 employees. And it is not like the runner-up has 10 employees either. We are talking about differences in several orders of magnitude. The way you make your point about hiring a regulatory expert seems to be designed to put in a gratuitous dig at the salaries (which are worthy of criticism even though in 2012 they were "only" mid six figures). They do not seem to be stressed at raising the relatively small amount of money that they need to cover their "burn rate" (which is mostly salaries), and there is no apparent reason that they would have to take a 55k salary cut to spend another 220k. Like I said in my previous post, the main issue is if things are not getting done or taking longer than they need to take because PVCT is slow to do what it has to do. My impression is that this is not the case. Peter is busy (as he should be) but does not seem overly stressed by his responsibilities. They are getting help with their science from Moffitt. It is, or should be, clear that the only real answer to everything is if they succeed, meaning that they sell out for a high price, like they think it is worth. They are not going to sell out on the cheap. They are not going to try to cash in for themselves by raising money in equity sales. It seems that they may/will be able to get some sort of PIII procedure approved without spending any additional money. Then the question is if that approval can be leveraged into some sort of cash to fund operations going forward.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next